Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with
advanced clear cell renal cell carcinoma using RECIST criteria.